Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

HIV Infections Clinical Trials

A listing of HIV Infections medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (55) clinical trials

PD-1 Inhibition to Determine CNS Reservoir of HIV-Infection

Objective In this Phase I, proof-of-concept study, we aim to determine the safety and tolerability of pembrolizumab, an FDA-approved monoclonal antibody against programmed cell death protein (PD)-1, in viremically suppressed human immunodeficiency virus-1 (HIV) positive patients. We will also examine the correlation of immune activation and suppression markers in viremically ...

Phase

2-5 Intermittent Caloric Restriction for Weight Loss and Insulin Resistance in HIV-Infected Adults With Features of the Metabolic Syndrome

The high prevalence of obesity coupled with chronic inflammation and immune activation places human immunodeficiency virus (HIV)-infected individuals at increased risk for metabolic complications emphasizing the need for more aggressive management of obesity and related co-morbidities in the aging HIV-infected population. The most effective treatment for obesity and metabolic syndrome ...

Phase

HIV-1 Specific T -Cells (HST-NEETs) for HIV-Infected Individuals

Treatment Description: This is a phase I, multi-site, study of the safety, immunologic and virologic responses of ex vivo expanded HIV-1 multi-antigen specific T-cell therapy (HST-NEET) as a therapeutic strategy in HIV-infected individuals suppressed on ART. Patients will be screened for eligibility in Step 1 and undergo a blood draw ...

Phase

Study to Assess Safety and Activity of Combination Therapy of VRC07-523LS and Vorinostat on HIV-infected Persons

This is a phase I, single-site, open-label study to evaluate the effects of VOR given in combination with VRC07-523LS on persistent HIV-1 Infection in HIV-infected individuals suppressed on ART. The investigators hypothesize that combination therapy with VRC07-523LS and VOR will be safe and well-tolerated by HIV-1-infected participants suppressed on ART. ...

Phase

Safety Tolerability Pharmacokinetics and Anti-Retroviral Activity of MK-8558 Monotherapy in Anti-Retroviral-Na ve HIV-1 Infected Participants (MK-8558-002)

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and anti-retroviral activity of MK-8558 monotherapy in anti-retroviral-nave HIV-1 infected participants. The primary hypothesis is that at a dose that exhibits an acceptable safety and tolerability profile, MK-8558 has superior anti-retroviral activity compared to historical placebo data.

Phase

Modelling the Interaction Between Rationally-designed Synthetic Model Viral Protein Immunogens

One of the most effective arms of the human immune system is the ability of very low concentrations of antibody proteins to bind to viruses, bacteria and toxins and "neutralise" their activity or ability to infect. In contrast to cellular immunity, which may cause tissue destruction and pathology, antibody-mediated immunity ...

Phase

Pharmacokinetic Safety and Efficacy of B/F/TAF in HIV-1 Infected Virologically Suppressed Pregnant Women in Their Second and Third Trimesters

The primary objective of this study is to evaluate the steady state pharmacokinetics of bictegravir (BIC) and confirm the dose of BIC/emtricitabine/tenofovir alafenamide (B/F/TAF) 50/200/25 mg fixed dose combination (FDC) in HIV-1 infected, virologically suppressed pregnant women in their second and third trimesters.

Phase

Evaluation of the Safety Tolerability and Pharmacokinetics (PK) of GSK3732394 First-Time-in-Human (FTIH) Study

This is a phase 1, 2 part, double-blind (sponsor-unblinded), randomized, placebo-controlled, FTIH study in a combined single-ascending and multiple-ascending dose to assess the safety, tolerability, and PK/pharmacodynamics (PD) attributes of GSK3732394 in healthy subjects. The data gathered in this study will further enable clinical development of GSK3732394 in HIV-infected subjects. ...

Phase

Safety Pharmacokinetics and Antiviral Activity of GS-6207 Administered Subcutaneously in HIV-1 Infected Adults

This study has 2 parts: Part A (Cohorts 1-5) and Part B (Cohorts 6-8). The primary objectives of this study are: Part A: To evaluate the short-term antiviral activity of GS-6207 compared to placebo in HIV-1 infected adults who are antiretroviral treatment naive or are experienced but capsid inhibitor (CAI) ...

Phase

Effect of GSK3640254 on the Pharmacokinetics of a Combination Oral Contraceptive

This is an open-label, single-sequence, 1-way drug-drug interaction study to investigate the effect of GSK3640254 on the pharmacokinetics of a combination oral contraceptive containing ethinyl estradiol (EE) and levonorgestrel (LNG). Effective contraception for women infected with human immunodeficiency virus (HIV) is important in the prevention of unplanned pregnancies. The study ...

Phase